Summit Therapeutics Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 36.6 million compared to USD 19.3 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.07 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.86 USD | +8.73% | +10.29% | +47.89% |
Apr. 11 | Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors | CI |
Apr. 09 | Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed | RE |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+47.89% | 2.71B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Summit Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023